Defence announces closing of securities for debenture financing

Vancouver, british columbia--(newsfile corp. - november 22, 2024) - defence therapeutics inc. (cse: dtc) (otcqb: dtcff) (fse: dtc) ("defence" or the "company"), a canadian biopharmaceutical company developing radiopharmaceuticals and adc products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it has closed its offering of unsecured convertible debentures (the "new debentures") for aggregate gross proceeds of cad$1,476,000 (the "offering") in consideration for the settlement of the principal amounts owing to holders of the previous debentures (as defined below) (the "outstanding debt").
DTC Ratings Summary
DTC Quant Ranking